DiaSorin wins FDA clearance and DiaSorin stock costs EUR 77.79

Published on 10/20/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin won FDA clearance for two Parvovirus B19 tests on LIAISON XL. DiaSorin stock costs EUR 77.79 on October 20, 2026.

FDA clearance and corporate dates

DiaSorin received FDA clearance for two Parvovirus B19 tests on October 13, 2026.
DiaSorin completed a EUR 250.0 million buyback covering 3,790,952 shares on October 7, 2026.
DiaSorin stock trades at EUR 77.79 at 10:16 a.m. CEST at Lang & Schwarz on October 20, 2026.
DiaSorin scheduled approval of third-quarter 2026 results for November 12, 2026.

DiaSorin, IT0003492391, Illustration mit AI erstellt.

DiaSorin (ISIN IT0003492391) was trading at EUR 77.79 at Lang & Schwarz on October 20, 2026, at 10:16 a.m. CEST. The company had received US FDA clearance on October 13, 2026, for two automated Parvovirus B19 serology tests on its LIAISON XL system, according to DiaSorin.

Three dated moves shape the story

On October 5, 2026, DiaSorin disclosed purchases of 40,523 treasury shares for EUR 3.07 million. On October 7, 2026, FinancialFilings reported completion of the EUR 250.0 million buyback, involving 3,790,952 shares, or 6.78 percent of the share capital. On October 13, 2026, the FDA clearance added two Parvovirus B19 tests to the LIAISON XL portfolio, according to MarketScreener.

What does the clearance add?

The new tests detect IgM and IgG antibodies against human Parvovirus B19 and were already available in the United States after authorization. MarketScreener said the automated format can deliver results on the same day, giving laboratories a faster route to diagnosis and treatment decisions.

DiaSorin's investor page lists fiscal year 2025 revenue of EUR 1,195 million, adjusted EBITDA of EUR 394 million, adjusted net profit of EUR 223 million and free cash flow of EUR 209 million. Those figures frame the FDA decision as a portfolio expansion for a diagnostics company with an established financial base.

When are the next results due?

FinancialFilings reported on October 5, 2026, that DiaSorin scheduled approval of its third-quarter 2026 results for November 12, 2026. The conference call is planned for the same date, with its time to be communicated separately.

Stock price and valuation

DiaSorin's market capitalization was EUR 3.8 billion as of October 20, 2026. The same quote showed a 52-week range of EUR 52.34 to EUR 79.72, placing the current euro quotation below the upper end of that interval.

The stock was trading at EUR 77.79 at Lang & Schwarz on October 20, 2026, at 10:16 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.